Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Peg-interferon improves liver in Hep B e antigen-positive Hep B

Peg-interferon α-2b improves liver necroinflammation, and fibrosis in Hep B e-antigen-positive Hep B, particularly in responders, however combination therapy with lamivudine does not further improve outcomes, finds May's Liver International.

News image

fiogf49gjkf04

The effect of Pegylated interferon (Peg-interferon) α-2b or its combination with lamivudine on liver histology of patients with chronic Hepatitis B is unknown.

Dr Monika van Zonneveld and colleagues from the Netherlands conducted a double-blinded, randomized, multi-center study.

The investigators assessed histological changes in 110 Hepatitis B e-antigen-positive chronic Hepatitis B patients.

The patients were treated for 52 weeks with Pegylated interferon α-2b in combination with either lamivudine or as monotherapy with placebo.

Liver biopsies were taken before and at the end of treatment.

All biopsies were blinded and scored according to the Ishak system.

The team found that the combination of Pegylated interferon α-2b with lamivudine improved necroinflammatory scores in 48% of patients.

The necroinflammatory score improved in 53% of patients of the Pegylated interferon α-2b monotherapy group.

Peg-interferon α-2b monotherapy improved necroinflammation in 78% of responders
Liver International

The investigators observed that fibrosis score improved in 33% of patients of the combination therapy group vs 22% of patients of the monotherapy group.

The team reported 42 responders, defined as serum Hepatitis B e-antigen negative at the end of therapy.

Responders showed a larger decline in necroinflammatory score than non-responders.

Among patients receiving Pegylated interferon α-2b monotherapy, necroinflammation improved in 78% of responders vs 43% of non-responders.

The team noted that with monotherapy, necroinflammation improved in 76% of patients with normal alanine transferase levels.

Necroinflammation improved only in 40% of patients with abnormal alanine transferase levels, and receiving monotherapy.

The investigators noted that fibrosis scores in the Pegylated interferon α-2b monotherapy group improved more often in responders than in non-responders.

In the combination therapy group, the team found no significant association between virological and biochemical endpoints and histological improvement.

Dr van Zonneveld's team concluded, “Treatment with Pegylated interferon α-2b therapy improves liver necroinflammation in Hepatitis B e-antigen-positive chronic Hepatitis B patients, particularly in responders to therapy.”

“Pegylated interferon α-2b also improves fibrosis in responders.”

“Addition of lamivudine to Pegylated interferon α-2b did not further improve the histological outcome.”

Liver Int 2006: 26(4): 399
26 April 2006

Go to top of page Email this page Email this page to a colleague

 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Management of hemorrhoids in the USA
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication
 23 January 2018 
Ectopic pregnancy in women with IBD
 23 January 2018 
Celiac disease in IBS in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us